图集:国外的一些异型淋巴细胞(反应性淋巴细胞)

2022-07-11 UJS医学检验毕业生 网络

一般来说,我们将“Atypical lymphocyte”翻译为“异型淋巴细胞”,将“Reactive lymphocyte”翻译为“反应性淋巴细胞”。异常淋巴细胞形态迥异,各有不同,下面这些图片,让

一般来说,我们将“Atypical lymphocyte”翻译为“异型淋巴细胞”,将“Reactive lymphocyte”翻译为“反应性淋巴细胞”。

 

小编认为,异型淋巴细胞+刺激性淋巴细胞(或称为“激活淋巴细胞”)=反应性淋巴细胞:

 

图片

下面,让我们来具体看看反应性淋巴细胞的图片:

 

欧洲白血病网(ELN)提供的反应性淋巴细胞图片(414、496、505):

 

图片

图片

图片

 

国际血液学标准化委员会(ICSH)提供的反应性淋巴细胞图片:

图片

 

 

美国血液学会(ASH)图片库(Image Bank)提供的反应性淋巴细胞(异型淋巴细胞)图片

 

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

图片

 

 

文献中的反应性淋巴细胞(异型淋巴细胞)图片

 

《Reactive lymphocytes in patient with COVID-19》:

图片

异型淋巴细胞的新病因:严重急性呼吸综合征冠状病毒2型

 

《Acute hepatitis associated with increased atypical lymphocyte》:

图片

图片

 

《Atypical lymphocyte morphology in SARS-CoV-2 infection》:

图片

图片

 

《Atypical lymphocytes in peripheral blood of patients with COVID-19》:

图片

图片

图片

图片

图片

 

《Performance Evaluation of High Fluorescence Lymphocyte Count: Comparability to Atypical Lymphocyte Count and Clinical Significance》:

图片

图片

 

《Reactive lymphocytes in an allergic drug reaction》:

图片

图片

图片

图片

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022880, encodeId=a8f3202288021, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 02 20:55:49 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099226, encodeId=f12c20992260c, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0656410341, createdName=ms6000002083289368, createdTime=Tue Nov 08 18:01:25 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242098, encodeId=c4fc1242098be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87568233773, createdName=ms7000001346984084, createdTime=Tue Aug 30 17:41:30 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302447, encodeId=a9f0130244ef5, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jul 13 05:55:49 CST 2022, time=2022-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022880, encodeId=a8f3202288021, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 02 20:55:49 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099226, encodeId=f12c20992260c, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0656410341, createdName=ms6000002083289368, createdTime=Tue Nov 08 18:01:25 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242098, encodeId=c4fc1242098be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87568233773, createdName=ms7000001346984084, createdTime=Tue Aug 30 17:41:30 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302447, encodeId=a9f0130244ef5, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jul 13 05:55:49 CST 2022, time=2022-07-13, status=1, ipAttribution=)]
    2022-11-08 ms6000002083289368

    学习了,谢谢。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2022880, encodeId=a8f3202288021, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 02 20:55:49 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099226, encodeId=f12c20992260c, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0656410341, createdName=ms6000002083289368, createdTime=Tue Nov 08 18:01:25 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242098, encodeId=c4fc1242098be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87568233773, createdName=ms7000001346984084, createdTime=Tue Aug 30 17:41:30 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302447, encodeId=a9f0130244ef5, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jul 13 05:55:49 CST 2022, time=2022-07-13, status=1, ipAttribution=)]
    2022-08-30 ms7000001346984084

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2022880, encodeId=a8f3202288021, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 02 20:55:49 CST 2022, time=2022-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2099226, encodeId=f12c20992260c, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d0656410341, createdName=ms6000002083289368, createdTime=Tue Nov 08 18:01:25 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242098, encodeId=c4fc1242098be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87568233773, createdName=ms7000001346984084, createdTime=Tue Aug 30 17:41:30 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302447, encodeId=a9f0130244ef5, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Jul 13 05:55:49 CST 2022, time=2022-07-13, status=1, ipAttribution=)]

相关资讯

DCR:淋巴细胞与 C 反应蛋白的比率是转移性结直肠癌患者中最敏感的预后指标

我们已经知道全身炎症有助于恶性肿瘤的进展。术前淋巴细胞与 C 反应蛋白的比率最近已被证明可以预测接受手术的结直肠癌患者的生存率

Cell Death & Differentiation:孙强/黄红艳/刘良团队合作揭示新冠患者淋巴细胞减少症发生的新机制

近日,北京生物工程研究所孙强研究员与首都医科大学黄红艳教授、华中科技大学同济医学院刘良教授团队合作,在 Cell Death & Differentiation 期刊发表了题为:SARS-CoV-2

Allergy:鼻内皮质激素治疗对2型先天淋巴细胞的影响研究

过敏性鼻炎具有鼻出血、鼻塞、打喷嚏和鼻腔瘙痒的特征。鼻腔过敏原挑战(NAC)后,鼻黏膜中的2型先天淋巴细胞(ILC2s)、CD4+T细胞和嗜酸性粒细胞均显著增加。但鼻腔内皮质激素(INCS)对ILC2

Allergol Immunopathol (Madr):过敏性鼻炎严重度与中性粒细胞/淋巴细胞、嗜酸性粒细胞/中性粒细胞和嗜酸性粒细胞/淋巴细胞比率的关系

调查了中性粒细胞与淋巴细胞比率(NLR)、嗜酸粒细胞与中性粒细胞比率(ENR)和嗜酸粒细胞与淋巴细胞比率(ELR)这三个炎症参数是否能够区分间歇过敏性鼻炎和持续过敏性鼻炎。

Clin Nutrition:术后早期肠内免疫营养对T淋巴细胞计数的改善效果分析

心脏外科手术患者,尤其是在体外循环下进行的外科手术患者,会经历不同的对各种生理功能的负面影响。

淋巴细胞增多背后的原因——大颗粒淋巴细胞

当患者血常规中淋巴细胞增多,且在血涂片中发现比例较高LGL,需要排除有克隆性疾病可能。